SENSEX NIFTY

Trastuzumab

Feb 07, 2014 at 22:27 | Source: CNBC-TV18
The Delhi High Court (HC) has thrown a wrench into plans of Biocon and Mylan to market a breast cancer drug that goes by the scientific name Trastuzumab.
Feb 04, 2014 at 09:59 | Source: PTI
The company's subsidiary Mylan Pharmaceuticals Pvt Ltd has launched the world's first trastuzumab biosimilar, which will be marketed by Mylan under the brand name Hertraz Herceptin, a company statement said.
Jan 18, 2014 at 16:21 | Source: Reuters
Bangalore-based Biocon jointly developed biosimilar trastuzumab, which received the Indian drug regulator's marketing approval in November, with US-based Mylan Inc.
Nov 26, 2013 at 14:42 | Source: Moneycontrol.com
Biocon has received marketing authorization from the Drugs Controller General of India for its Biosimilar Trastuzumab being developed jointly with Mylan, for treatment of Her 2+ metastatic breast cancer.
Messages on Trastuzumab »

sanecounsel

Platinum Member

76 Followers

Biocon  

the outcome of the Delhi High Court case brought by Roche against Biocon and Mylan in February gains significance. Roche has alleged that Biocon/Mylan has misrepresented its drugs as a biosimilar of its bestselling breast cancer drug, Trastuzumab (Herceptin), without having undergone the required

10.04 AM Jul 8th

namo8081

New Member

3 Followers

Biocon  

biocon will be selling trastuzumab and glargine in emerging market and rh insulin in EM and EU both.therefore thise who r holding this stock shd plan their trade accordingly. exit at 22-25 p e and reenterbelow 20

12.31 PM Apr 4th

unseenvalue

Gold Member

94 Followers

Biocon  

Biocon should be 10X in next 3 years to compensate for the pain over these years. Unless it delivers against all potential triggers (ItolizuMab, IN105, TrastuzuMab etc) over the next 2/3 years - i for one can`t see 4000 on the screen. Can you Stocktin, Akrmr ?

1.38 PM Apr 3rd

srikanth031
086

Gold Member

62 Followers

Biocon  

trastuzumab. The company was, however, confident that the injunction limiting promotional activities would not stand in Court, once they were heard.

12.32 PM Feb 10th

sanecounsel

Platinum Member

76 Followers

Biocon  

version of Trastuzumab, in the Indian market until the disposal of the present suit, and also sought an injunction restraining the said defendants from relying upon or otherwise referring to HERCEPTIN®, HERCLONTM or BICELTIS® or any data relating to Trastuzumab marketed as HERCEPTIN®, HERCLONTM

10.48 PM Feb 8th

srikanth031
086

Gold Member

62 Followers

Biocon  

. “It is an extremely shocking, but not unexpected development. This proceeding is an attempt by Roche to protect their market monopoly and prevent Indian patients from accessing a more affordable trastuzumab,” Biocon said in a statement

1.50 PM Feb 8th

Web Messenger

Platinum Member

252007 Followers

Biocon  

Source:Economic Times - NEW DELHI: Biocon`s launch of the world`s first bio-similar of Trastuzumab, a critical breast cancer drug, is unlikely to benefit patients in a big way if the company sticks to the prices it has indicated, claimed health activists on Monday. They allege that Roche, which

1.54 PM Jan 21st

Neha-Diwan

Platinum Member

810 Followers

Biocon  

Biocon shines on introducing world’s first biosimilar trastuzumab `CANMAb`.

12.17 PM Jan 20th

BSE/NSE Announcer

Platinum Member

5239 Followers

Biocon  

Biocon Limited has informed the Exchange regarding a press release dated January 18, 2014, titled"Biocon introduces CANMAb - Worlds First Biosimilar Trastuzumab for Treating Breast Cancer in India".

10.28 AM Jan 20th

BSE/NSE Announcer

Platinum Member

5239 Followers

Biocon  

Biocon Ltd has informed BSE regarding a Press Release dated January 18, 2014 titled "Biocon introduces CANMAb™ - Worlds First Biosimilar Trastuzumab for Treating Breast Cancer in India".

12.52 PM Jan 18th

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.